SLC25A47 and type 2 diabetes mellitus: This tissue specificity makes SLC25A47 an attractive therapeutic target, considering the recent successful examples in which liver-targeting mitochondrial uncouplers protected mice against type 1 and type 2 diabetes, hepatic steatosis, and cardiovascular complications (47, –49).